Similar articles

• Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients.

  Racadot E, Milpied N, Bordigoni P, Cahn JY, Plouvier E, Lioure B, Lutz P, Wijdenes J, Herve P. Racadot E, et al. Bone Marrow Transplant. 1995 May;15(5):669-77. Bone Marrow Transplant. 1995. PMID: 7670394 Clinical Trial.
• Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor.

  Tiley C, Powles R, Teo CP, Treleaven J, Findlay M, Hewetson M. Tiley C, et al. Bone Marrow Transplant. 1991;7 Suppl 2:151. Bone Marrow Transplant. 1991. PMID: 1652326 No abstract available.
• Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.

  Herbelin C, Stephan JL, Donadieu J, Le Deist F, Racadot E, Wijdenes J, Fischer A. Herbelin C, et al. Bone Marrow Transplant. 1994 May;13(5):563-9. Bone Marrow Transplant. 1994. PMID: 8054909
• Perspectives in the prevention and treatment of acute graft versus host disease.

  Herve P. Herve P. Bone Marrow Transplant. 1991;7 Suppl 2:117-9. Bone Marrow Transplant. 1991. PMID: 1715225 Review. No abstract available.
• Current and novel therapies in acute GVHD.

  Ho VT, Cutler C. Ho VT, et al. Best Pract Res Clin Haematol. 2008 Jun;21(2):223-37. doi: 10.1016/j.beha.2008.02.009. Best Pract Res Clin Haematol. 2008. PMID: 18503988 Review.